Dzhumataeva Z A
Kazakh-Russian Medical University, 71 Torekulov St., Almaty, Kazakhstan, 050004.
Vestn Oftalmol. 2016 Jul-Aug;132(4):62-67. doi: 10.17116/oftalma2016132462-67.
to evaluate the effectiveness of prolatan (latanoprost 0.005%) in the treatment of primary open-angle glaucoma (POAG).
The study included 35 POAG patients (41 eyes) aged 55-72 years, of them 20 men and 15 women. The patients were randomized into two groups followed up for 3 months. Group 1 consisted of 17 patients (19 eyes) who received prolatan once daily in the evening. Group 2 consisted of 18 patients (22 eyes) under Xalatan 0.005% once daily in the evening.
The true intraocular pressure (IOP) decreased by the average of 28.6%. Analysis of perimetry results showed a statistically reliable increase in the MD - by 17.4% in the study group and by 20% in the control group, and PSD indices - by 10.7% and 11.9%, respectively. Optical coherence tomography revealed an improvement of optic disc parameters in both groups. In particular, the cup volume decreased reliably by 8.4% and 6.3% and cup area - by 24.4% and 28.5%, respectively, while the rim area increased by 20.8% and 17.9%, respectively. The patients complained of neither burning, nor discomfort, nor foreign body sensation after prolatan instillations. We also report the absence of side effects.
The study has proved high antihypertensive effectiveness of prolatan. Improved morphometric parameters of the optic disc (decreased cup volume and area, increased rim area) indirectly indicate the neuroprotective potential of the drug. Being well-tolerated by the patients, prolatan can be recommended as the first choice treatment of glaucoma.
评估普洛拉坦（0.005%拉坦前列素）治疗原发性开角型青光眼（POAG）的有效性。
该研究纳入了35例年龄在55至72岁之间的POAG患者（41只眼），其中男性20例，女性15例。患者被随机分为两组，随访3个月。第1组由17例患者（19只眼）组成，他们在晚上每天使用一次普洛拉坦。第2组由18例患者（22只眼）组成，晚上每天使用一次0.005%的适利达。
真实眼压（IOP）平均降低了28.6%。视野检查结果分析显示，平均缺损（MD）有统计学意义的可靠增加——研究组增加了17.4%，对照组增加了20%，模式标准差（PSD）指数分别增加了10.7%和11.9%。光学相干断层扫描显示两组视盘参数均有改善。特别是，杯状凹陷体积分别可靠地减少了8.4%和6.3%，杯状凹陷面积分别减少了24.4%和28.5%，而视盘边缘面积分别增加了20.8%和17.9%。患者在滴入普洛拉坦后既没有抱怨烧灼感、不适感，也没有异物感。我们还报告未出现副作用。
该研究证明了普洛拉坦具有较高的降压有效性。视盘形态测量参数的改善（杯状凹陷体积和面积减小，视盘边缘面积增加）间接表明了该药物的神经保护潜力。由于患者耐受性良好，普洛拉坦可被推荐为青光眼的首选治疗药物。
